Division of Amgen Inc.
Latest From Alantos Pharmaceuticals
In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for April-June 2007. Our data come from Windhover's Strategic Transactions Database. Look for our quarterly review on the medical device, in vitro diagnostics, and research industries in upcoming issues.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
It was always a question of when, not if. Amgen needed to do something to provide for its post-EPO future; now the action has started. The big biotech went on a $720 million cash shopping spree in the early part of June, buying first Ilypsa Inc. for $420 million, then swallowing up Alantos Pharmaceuticals for $300 million a couple of days later.
Two of Europe's handful of IPOs this season are struggling to stay afloat. Bankruptcies continue among private German biotechs. Yet VCs have more money than ever and two of the European biotech flotations were the second- and third-largest globally during this window. What do Europe's biotechs need to do in this new, cautious and contradictory era in order to raise private funds and survive on the open markets? In Vivo Europe Rx asked three top leading European financiers.
- Therapeutic Areas
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Therascope AG
- North America
- Parent & Subsidiaries
- Amgen Inc.
- Senior Management
Keith E Dionne, PhD, Pres. & CEO
Neil Exter, CBO
Arthur Tareras, PhD, VP, Drug Discovery
- Contact Info
Phone: (617) 577-0011
840 Memorial Dr.
Cambridge, MA 02139